Daewoong Pharmaceutical Performance dei guadagni passati

Il passato criteri di controllo 4/6

Daewoong Pharmaceutical ha registrato una crescita degli utili a un tasso medio annuo di 50.8%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 7.8%. I ricavi sono stati in crescita a un tasso medio annuo di 6.4%. Il ritorno sul capitale proprio di Daewoong Pharmaceutical è 10.2% e ha margini netti di 7.3%.

Informazioni chiave

50.8%

Tasso di crescita degli utili

49.6%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	11.3%
Tasso di crescita dei ricavi	6.4%
Rendimento del capitale proprio	10.2%
Margine netto	7.3%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

Nov 22

Recent updates

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

Nov 22

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Nov 06

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Oct 15

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 13

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Jul 24

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Jul 04

Ripartizione dei ricavi e delle spese

Come Daewoong Pharmaceutical guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

KOSE:A069620 Ricavi, spese e utili (KRW Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	1,416,626	103,573	401,363	172,772
30 Jun 24	1,399,052	90,872	391,892	173,867
31 Mar 24	1,388,699	114,474	392,725	168,094
31 Dec 23	1,375,329	121,739	383,418	171,573
30 Sep 23	1,341,290	46,381	469,048	83,115
30 Jun 23	1,332,284	51,305	443,718	111,741
31 Mar 23	1,304,151	44,030	375,154	170,379
31 Dec 22	1,280,092	42,240	368,342	163,602
30 Sep 22	1,255,325	82,107	353,493	147,550
30 Jun 22	1,214,081	72,576	336,475	137,991
31 Mar 22	1,181,714	61,231	326,622	132,725
31 Dec 21	1,152,976	24,506	317,559	127,269
30 Sep 21	1,117,201	11,539	307,310	126,287
30 Jun 21	1,103,387	2,971	299,168	125,983
31 Mar 21	1,067,635	-11,030	294,321	122,936
31 Dec 20	1,055,424	12,753	302,954	115,218
30 Sep 20	1,075,831	-1,657	307,612	115,679
30 Jun 20	1,068,433	-2,480	321,931	111,557
31 Mar 20	1,107,158	16,828	322,501	107,536
31 Dec 19	1,113,426	22,006	311,748	109,441
30 Sep 19	1,098,180	-8,021	300,878	109,633
30 Jun 19	1,086,724	-6,314	279,069	110,241
31 Mar 19	1,055,675	-12,079	266,121	110,137
31 Dec 18	1,031,427	-15,152	255,892	112,961
30 Sep 18	995,896	19,610	245,052	112,661
30 Jun 18	990,152	25,296	246,327	114,741
31 Mar 18	973,800	31,077	244,366	114,720
31 Dec 17	960,307	31,581	246,833	107,939
30 Sep 17	959,672	39,318	238,630	108,184
30 Jun 17	927,950	34,453	234,693	104,439
31 Mar 17	898,632	27,433	234,233	101,974
31 Dec 16	883,920	26,970	229,623	103,691
30 Sep 16	862,689	19,704	240,559	91,898
30 Jun 16	869,026	26,021	235,219	73,045
31 Mar 16	857,252	34,413	223,333	51,712
31 Dec 15	839,686	42,930	215,954	31,068
30 Sep 15	812,337	44,657	205,139	17,129
30 Jun 15	778,975	28,576	201,929	15,271
31 Mar 15	758,475	30,555	197,536	17,819
31 Dec 14	735,889	31,544	193,043	18,743
30 Sep 14	734,716	31,176	189,697	20,823
30 Jun 14	714,185	56,700	184,260	20,873
31 Mar 14	690,275	58,808	185,059	20,249
31 Dec 13	682,508	58,400	190,100	21,170

Guadagni di qualità: A069620 ha un livello elevato di guadagni non monetari.

Margine di profitto in crescita: Gli attuali margini di profitto netti di A069620 (7.3%) A069620 sono più alti rispetto allo scorso anno (3.5%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: A069620 è diventata redditizia negli ultimi 5 anni, aumentando i guadagni del 50.8% all'anno.

Accelerare la crescita: La crescita degli utili di A069620 nell'ultimo anno ( 123.3% ) supera la media quinquennale ( 50.8% all'anno).

Guadagni vs Settore: La crescita degli utili A069620 nell'ultimo anno ( 123.3% ) ha superato la percentuale del settore Pharmaceuticals 20.6%.

Daewoong Pharmaceutical Performance dei guadagni passati

Il passato criteri di controllo 4/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

Full year 2022 earnings released: EPS: ₩3,816 (vs ₩2,227 in FY 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

First quarter 2021 earnings released: ₩2,139 loss per share (vs ₩65.00 profit in 1Q 2020)

Full year 2020 earnings released: EPS ₩1,196 (vs ₩2,132 in FY 2019)

Third quarter 2020 earnings released: EPS ₩223

Recent updates

Hanall Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of A First-In-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Price target increased by 7.8% to ₩190,000

Price target increased by 11% to ₩176,250

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 19%

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-In-Class PRS Inhibitor, Bersiporocin

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 19%

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Consensus EPS estimates increase by 25%

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Upcoming dividend of ₩600 per share at 0.5% yield

Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-Dose Administration of Nabota

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy

Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

Price target decreased by 7.5% to ₩171,083

Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet

New minor risk - Shareholder dilution

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

Full year 2022 earnings released: EPS: ₩3,816 (vs ₩2,227 in FY 2021)

Now 20% undervalued after recent price drop

Price target decreased by 7.4% to ₩205,714

Investor sentiment deteriorates as stock falls 18%

Daewoong Pharmaceutical Begins the First Administration of Bersiporocin

Daewoong Pharmaceutical Co.,Ltd Submits NDA for Its Global New Drug Fexuclue in 11 Countries, Only 1 Year After Approval in Korea

Consensus forecasts updated

Upcoming dividend of ₩600 per share

Daewoong Pharmaceutical Announces Success in Developing New Antidiabetic Medication

Now 20% undervalued after recent price drop

Less than half of directors are independent

Daewoong Pharmaceutical Announces Phase 3 Clinical Trial Results of New Diabetes Treatment Enavogliflozin

Investor sentiment improved over the past week

Price target increased to ₩235,714

Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-In-Class Irreversible Oral Dual Acting Inhibitor for Autoimmune Diseases

Price target increased to ₩235,000

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

Investor sentiment improved over the past week

Less than half of directors are independent

Daewoong Pharmaceutical Submits NDA for its Global New Drug Fexuclue Tablets to the Philippines

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Daewoong pharmaceutical Co.,Ltd Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug

Upcoming dividend of ₩600 per share

Price target increased to ₩199,000

Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes

Daewoong Pharmaceutical of South Korea Announces PRS-Inhibitor for Idiopathic Pulmonary Fibrosis Shows Promising Result in Early Stage Clinical Test

First quarter 2021 earnings released: ₩2,139 loss per share (vs ₩65.00 profit in 1Q 2020)

Price target increased to ₩147,143

Evolus, Inc. and Daewoong Pharmaceuticals Co., Ltd. Enter into Settlement Agreement

Full year 2020 earnings released: EPS ₩1,196 (vs ₩2,132 in FY 2019)

Daewoong pharmaceutical Co.,Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩121,000

Price target raised to ₩126,625

New 90-day high: ₩119,000

Third quarter 2020 earnings released: EPS ₩223

Price target lowered to ₩110,000

New 90-day low: ₩91,900

Daewoong Pharmaceutical Announces Korea's First-Ever SGLT2 Inhibitor for Diabetes Treatment

Price target lowered to ₩123,214

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato